- Infinity Pharmaecuticals (NASDAQ:INFI) provides a business update ahead of a presentation at the JPMorgan healthcare conference.
- The company says it anticipates moving into earlier lines of therapy, new indications and novel, potentially transformative immuno-oncology combinations to execute on our strategy to expand the depth and breadth of the development of IPI-549.
- "Importantly, we have a cash runway into the second half of 2020, which enables us to advance IPI-549 development in several innovative studies in 2019. We also have the support of tremendous collaborators BMS and Arcus for two of these potentially transformative studies," says CEO Adelene Perkins
- Infinity also plans to advance novel triple combination therapies with Arcus, initially evaluating IPI-549 in combination with AB928, Arcus's dual adenosine receptor antagonist, and chemotherapy in patients with previously treated, advanced triple negative breast cancer.
- Infinity sets guidance for 2019 for a net loss $30M to $40M and year-end cash $20M to $30M. A cash runway is anticiapted into the second half of 2020.
- Source: Press Release
- #JPM19